منابع مشابه
Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer
Pancreatic cancer, most commonly referring to pancreatic ductal adenocarcinoma (PDAC), remains one of the most deadly diseases, with very few effective therapies available. Emerging as a new modality of modern cancer treatments, immunotherapy has shown promises for various cancer types. Over the past decades, the potential of immunotherapy in eliciting clinical benefits in pancreatic cancer hav...
متن کاملThe immuno-oncology framework
Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, descr...
متن کاملAdvancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
Immuno-oncology (I-O) is a young and growing field on the frontier of cancer therapy. Contrary to cancer therapies that directly target malignant cells, I-O therapies stimulate the body's immune system to target and attack the tumor, which is otherwise invisible to, or inhibiting the immune response. To this end, several methods have been developed: First, passive therapies that enable T-cells ...
متن کاملMevalonate Metabolism in Immuno-Oncology
Immuno-oncology not only refers to the multifaceted relationship between our immune system and a developing cancer but also includes therapeutic approaches that harness the body's immune system to fight cancer. The recognition that metabolic reprogramming governs immunity was a key finding with important implications for immuno-oncology. In this review, we want to explore how activation and dif...
متن کاملImmunomedics Awarded U.s. Patent for Novel Immuno- Oncology Agents for Cancer Therapy
The new invention concerns methods of use of T-cell redirecting bispecific antibodies, created with the Company’s proprietary DOCK-AND-LOCK (DNL) protein conjugation platform technology. The issued claims cover use of DNL complexes that simultaneously bind to the CD3 T-cell antigen and the Trop-2 tumor antigen, which is expressed by many solid cancers. The claims specifically cover use of the C...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2020
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon-2020-0545